ANGO

AI Memo

AngioDynamics

As of 2026-09-13/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-13 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

NanoKnife reimbursement and clinical execution • 2027-05-31

Base target: $17 / p=50% prob

Biggest risk

ANGO remains loss-making on an adjusted per-share basis, Med Device growth was modest, thrombectomy performance was uneven in stored earnings coverage, and tariffs or commercialization costs could delay durable profitability. The July 30 open-market sale by the SVP of Quality and Regulatory is a monitoring item, not evidence of deteriorating operations [#SEC-FORM4-2026-07-31].

Invalidation

Break below $11 or thesis failure.

What would change my mind?

Record fiscal 2026 revenue, 18.4% pro forma Med Tech growth, positive adjusted EBITDA, NanoKnife reimbursement progress, and multiple clinical programs provide several routes to sustained growth. Fourth-quarter revenue reportedly exceeded the cited consensus by 7.6%, while adjusted loss per share was narrower than that consensus, though that comparison comes from stored third-party earnings context rather than a company filing.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-13

Base target

$17

p=50%

Bull target

$21

p=30%

Bear target

$11

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Growth fails to produce consistent profitability
Med Tech growth converts into durable operating leverage
Record fiscal 2026 revenue, 18.4% pro forma Med Tech growth, positive adjusted EBITDA, NanoKnife reimbursement progress, and multiple clinical programs provide several routes to sustained growth.

BearKey bullets

Analyst coverage is thin or unavailable, with no verified post-print estimate revisions or target-change history.
Clinical trials and IDE-stage programs carry enrollment, execution, regulatory, and commercialization risk; the packet provides no specific readout calendar.
Commercial adoption may not accelerate sufficiently following NanoKnife Medicare coverage, and no utilization data after the July 5, 2026 effective date were supplied.

WatchKey bullets

NanoKnife reimbursement and clinical execution

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $17 (p=50%)

Target spread vs base: +24% / -35%

Scenario probabilities

Bull Target: $21 (p=30%)Base Target: $17 (p=50%)Bear Target: $11 (p=20%)

Commentary

Primary filing evidence is constructive on Med Tech growth, profitability progress, reimbursement, and clinical milestones. Stored third-party coverage reported that shares gained about 8.9% during the month following earnings, although the immediate after-hours reaction was flat. No reliable social, options-skew, short-interest, employee-sentiment, or post-earnings analyst-revision data were supplied; the zero sentiment fields therefore indicate unavailable inputs rather than neutral readings. With the shares already above the July insider-sale prices and forward adoption evidence still limited, sentiment supports cautious monitoring rather than a high-conviction upgrade.

As of 2026-09-13 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Growth fails to produce consistent profitability
Med Tech growth converts into durable operating leverage

Scenarios

Bull Target (Scenario probability)

$21 / p=30% prob

Base Target (Scenario probability)

$17 / p=50% prob

Bear Target (Scenario probability)

$11 / p=20% prob

Analysis 2026-09-13 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-05-31
NanoKnife reimbursement and clinical execution
The Medicare coverage determination for qualifying NanoKnife prostate and liver cancer procedures became effective July 5, 2026, while the company also reported IDE approvals and multiple trial initiations. Evidence of resulting hospital adoption, probe utilization, and continued trial execution could validate the commercial opportunity; specific readout timing was not supplied [#SEC-8K-2026-07-14].
Prob 60.00% • Move 16.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Growth fails to produce consistent profitability
2027-05-31
Fourth-quarter adjusted loss was $0.07 per share, Med Device revenue grew only 1.1% pro forma, and management cited tariff-related headwinds. Slower Med Tech momentum or inadequate operating leverage could reverse the post-earnings rerating [#SEC-8K-2026-07-14].
Prob 40% • Move -18% • Priced-in 35%

Long-term Catalysts

Months to a year

Med Tech growth converts into durable operating leverage
2027-05-31
Fiscal 2026 Med Tech sales grew 18.4% pro forma, adjusted EBITDA reached $13.2 million, and year-end cash was $53.9 million. Sustained Auryon and NanoKnife growth with further margin improvement could support a higher valuation, but the thesis remains dependent on execution by a low-coverage small-cap issuer [#SEC-8K-2026-07-14].
Prob 55% • Move 24% • Priced-in 35%

Risks

Analyst coverage is thin or unavailable, with no verified post-print estimate revisions or target-change history.
Clinical trials and IDE-stage programs carry enrollment, execution, regulatory, and commercialization risk; the packet provides no specific readout calendar.
Commercial adoption may not accelerate sufficiently following NanoKnife Medicare coverage, and no utilization data after the July 5, 2026 effective date were supplied.
Continued adjusted losses could persist if Med Tech growth slows or operating leverage fails to offset commercialization and tariff-related costs.
Med Device produced only 1.1% pro forma fourth-quarter growth, leaving consolidated performance increasingly dependent on the faster-growing Med Tech platforms.

Peers

Symbol	Summary
BWAY	Similar-size health-care equipment comparator, but its neuromodulation exposure is not a direct match for AngioDynamics' vascular and interventional-oncology platforms; useful mainly for small-cap medtech valuation context.
KIDS	Similar-size medical-device comparator with execution and hospital-adoption relevance, although its orthopedic focus makes operating comparisons imperfect.
BSX	Relevant diversified cardiovascular-device benchmark for sector demand and innovation sentiment, but its scale, profitability, and breadth make it unsuitable as a direct valuation peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-13

Loading AI feed…

Symbol

Summary

BWAY

Similar-size health-care equipment comparator, but its neuromodulation exposure is not a direct match for AngioDynamics' vascular and interventional-oncology platforms; useful mainly for small-cap medtech valuation context.

KIDS

Similar-size medical-device comparator with execution and hospital-adoption relevance, although its orthopedic focus makes operating comparisons imperfect.

BSX

Relevant diversified cardiovascular-device benchmark for sector demand and innovation sentiment, but its scale, profitability, and breadth make it unsuitable as a direct valuation peer.